Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Teva
Deloitte
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Citi
Federal Trade Commission
QuintilesIMS
Farmers Insurance

Generated: December 12, 2017

DrugPatentWatch Database Preview

Valeant Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS, and what generic alternatives to VALEANT PHARMS drugs are available?

VALEANT PHARMS has forty-five approved drugs.

There are thirty-six US patents protecting VALEANT PHARMS drugs.

There are five hundred and twenty-two patent family members on VALEANT PHARMS drugs in forty-five countries and thirty-eight supplementary protection certificates in eleven countries.

Summary for Valeant Pharms

International Patents:522
US Patents:36
Tradenames:38
Ingredients:34
NDAs:45
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms NorthDILTIAZEM HYDROCHLORIDEdiltiazem hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL075116-004Dec 23, 1999AB3RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms NorthAPLENZINbupropion hydrobromideTABLET, EXTENDED RELEASE;ORAL022108-003Apr 23, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Valeant PharmsPENTOXIFYLLINEpentoxifyllineTABLET, EXTENDED RELEASE;ORAL075028-001Jul 20, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms NorthNIFEDIPINEnifedipineTABLET, EXTENDED RELEASE;ORAL076070-001Aug 16, 2002AB1RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms NorthXENAZINEtetrabenazineTABLET;ORAL021894-001Aug 15, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms IntlUCERISbudesonideTABLET, EXTENDED RELEASE;ORAL203634-001Jan 14, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Valeant Pharms LlcTASMARtolcaponeTABLET;ORAL020697-001Jan 29, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms NorthKLARONsulfacetamide sodiumLOTION;TOPICAL019931-001Dec 23, 1996ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms NorthTIAZACdiltiazem hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020401-004Sep 11, 1995AB4RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant Pharms IntlGIAZObalsalazide disodiumTABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms NorthDERMATOPprednicarbateOINTMENT;TOPICAL019568-001Sep 23, 1991► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms NorthRENOVAtretinoinCREAM;TOPICAL019963-001Dec 29, 1995► Subscribe► Subscribe
Valeant Pharms LlcTASMARtolcaponeTABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms LlcTASMARtolcaponeTABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcTASMARtolcaponeTABLET;ORAL020697-001Jan 29, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
balsalazide disodiumTablets1.1 gGIAZO11/5/2013
budesonideExtended-release Tablets9 mgUCERIS3/11/2013
mesalamineExtended-release Capsules0.375 gAPRISO4/3/2012
fluorouracilCream0.5%CARAC7/29/2011
bupropion hydrobromideExtended-release Tablets522 mgAPLENZIN12/24/2009
bupropion hydrobromideExtended-release Tablets174 mgAPLENZIN9/28/2009
bupropion hydrobromideExtended-release Tablets348 mgAPLENZIN9/24/2009
diazepamRectal Gel5 mg/mL, 2mL pre-filled syringeDIASTAT ACUDIAL12/23/2008
diazepamRectal Gel5 mg/mL, 4mL pre-filled syringeDIASTAT ACUDIAL12/8/2008
tramadol hydrochlorideExtended-release Tablets300 mgULTRAM ER9/25/2007
tramadol hydrochlorideExtended-release Tablets200 mgULTRAM ER3/28/2007
tramadol hydrochlorideExtended-release Tablets100 mgULTRAM ER1/8/2007
diazepamRectal Gel2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mLDIASTAT3/23/2004

Premature patent expirations for VALEANT PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Valeant Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,629,155 High-affinity oligonucleotide ligands to immunoglobulin E (IgE)► Subscribe
5,595,877 Methods of producing nucleic acid ligands► Subscribe
7,410,652Controlled release and taste masking oral pharmaceutical composition► Subscribe
5,811,533 High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)► Subscribe
5,864,026 Systematic evolution of ligands by exponential enrichment: tissue selex► Subscribe
7,884,136Modified-release formulations of a bupropion salt► Subscribe
5,472,841 Methods for identifying nucleic acid ligands of human neutrophil elastase► Subscribe
6,147,204 Nucleic acid ligand complexes► Subscribe
7,939,654Platelet derived growth factor (PDGF) nucleic acid ligand complexes► Subscribe
5,637,459 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Pharms Drugs

Country Document Number Estimated Expiration
Italy1317871► Subscribe
Canada2620091► Subscribe
JapanH08252100► Subscribe
Canada2739465► Subscribe
Israel129497► Subscribe
Spain2336857► Subscribe
JapanH11507529► Subscribe
Canada2315271► Subscribe
Australia5301996► Subscribe
Australia768414► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006 00021Denmark► Subscribe
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
/1999Austria► SubscribePRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
00152Netherlands► SubscribePRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C/GB04/012United Kingdom► SubscribePRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
252Luxembourg► Subscribe91252, EXPIRES: 20210131
2000 00018Denmark► SubscribePRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Queensland Health
QuintilesIMS
Teva
UBS
Colorcon
Cerilliant
Dow
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot